EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR -mutated non-small cell lung cancer

Camille Mehlman, Aurelie Swalduz, Isabelle Monnet, Clara Morin, Marie Wislez, Florian Guisier, Hubert Curcio, Pauline Du Rusquec, Alexis B Cortot, Valerie Gounant, Baptiste Abbar, Boris Duchemann und 5 weitere

The Oncologist · 2025

DOI: 10.1093/oncolo/oyae312 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Oncologist, 2025. Verfasst von Camille Mehlman und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pneumology and Thoracic Oncology, Tenon Hospital, Assistance Publique Hôpitaux de Paris and GRC 4, Theranoscan, Sorbonne Université, Pa…. Hauptthemen laut MEDLINE: Acrylamides, Aniline Compounds, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The emergence of diverse resistance mechanisms after osimertinib therapy, including on-target epidermal growth factor receptor (EGFR) mutations and off-target alterations, warrants investigation of novel therapeutics to overcome these challenges and improve patient outcomes.

Methods

COMPOSIT was a French, retrospective, multicenter, cohort study of the effectiveness and tolerability of osimertinib in combination with other targeted therapies in patients with advanced EGFR-mutant (EGFRm) non-small cell lung cancer (NSCLC) who harbored other oncogenic drivers as primary or acquired resistance mechanisms. Real-world progression-free survival (rwPFS), overall survival (OS), and objective response rate (ORR) were the primary endpoints.

Results

The study included 61 patients (63.9% women; median age, 61 years). Chemotherapy was administered to 26 patients (42.6%) before the combinations. The most frequently targeted resistance mechanisms were MET amplification (n = 40) and BRAF alterations (n = 11). Sixteen combinations of osimertinib with other targeted therapies were reported. Overall (except for 10 patients in clinical trials), median rwPFS and OS were 3.9 (95% CI, 2.9-5.2) and 9.8 months (95% CI, 6.8-14.8). Best ORR (n = 54) was 50% (95% CI, 33.0-72.8). In patients with MET amplification (n = 29), median rwPFS and OS were 4.9 (95% CI, 2.9-7.2) and 8.6 months (95% CI, 5.3-21.6). Grade ≥3 adverse events occurred in 15 patients (24.6%). No deaths were related to treatment.

Conclusions

Combinations of osimertinib with other targeted therapies appeared to be feasible and safe and may offer clinical benefit to overcome resistance to osimertinib in EGFRm NSCLC, especially in patients with MET amplification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcrylamidesAniline CompoundsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungLung NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedErbB ReceptorsMolecular Targeted TherapyMutationProtein Kinase InhibitorsRetrospective StudiesCohort StudiesIndolesPyrimidines

Stichwörter der Autor:innen

EGFR TKI resistanceEGFR mutationcombinationsnon-small cell lung cancerosimertinibreal-world study

Substanzen

AcrylamidesAniline CompoundsEGFR protein, humanErbB ReceptorsosimertinibProtein Kinase InhibitorsIndolesPyrimidines

Autor:innen und Institutionen

  • Department of Pneumology and Thoracic Oncology, Tenon Hospital, Assistance Publique Hôpitaux de Paris and GRC 4, Theranoscan, Sorbonne Université, Paris, France.
  • Department of Medical Oncology, Léon Bérard Cancer Centre, Lyon, France.
  • Univ Lyon, Claude Bernard Lyon 1 University, INSERM 1052, CNRS 5286, Centre Leon Bérard, Cancer Research Center of Lyon, Lyon, France.
  • Department of Pneumology, Centre Hospitalier Inter-Communal de Creteil (CHIC), Creteil, France.
  • Department of Thoracic Oncology, Centre Hospitalier Universitaire Larrey, Toulouse, France.
  • Unité d'Oncologie Thoracique Service de Pneumologie Hopital Cochin, AP-HP Equipe "cancer, immune control and escape" Inserm U1138 Centre de Recherches des Cordeliers Université Paris Cité, France.

ORCID-Profile: Vincent Fallet

Zitieren

APA

Mehlman, C., Swalduz, A., Monnet, I., Morin, C., Wislez, M., Guisier, F., Curcio, H., Du Rusquec, P., Cortot, A. B., Gounant, V., Abbar, B., Duchemann, B., Giroux-Leprieur, E., Pierret, T., Quilot, F. M., Cadranel, J., & Fallet, V. (2025). COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR -mutated non-small cell lung cancer. The Oncologist. https://doi.org/10.1093/oncolo/oyae312

Vancouver

Mehlman C, Swalduz A, Monnet I, Morin C, Wislez M, Guisier F, et al. COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR -mutated non-small cell lung cancer. The Oncologist. 2025. doi:10.1093/oncolo/oyae312

BibTeX
@article{Mehlman2025,
  author = {Mehlman, Camille and Swalduz, Aurelie and Monnet, Isabelle and Morin, Clara and Wislez, Marie and Guisier, Florian and Curcio, Hubert and Du Rusquec, Pauline and Cortot, Alexis B and Gounant, Valerie and Abbar, Baptiste and Duchemann, Boris and Giroux-Leprieur, Etienne and Pierret, Thomas and Quilot, Fleur-Marie and Cadranel, Jacques and Fallet, Vincent},
  title = {COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR -mutated non-small cell lung cancer},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyae312}
}
Kostenlos starten →